Howard G. Welgus sold $114k of ARQT
director at Arcutis Biotherapeutics, Inc.. 4,730 shares at an average of $24.18, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +10Trade size$114k at market
- +5Share of holdings soldSold 12% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-062490, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +822 | $6.52 | $5,361 | 37,297 | 25 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +1,019 | $7.51 | $7,653 | 38,316 | 25 d ago |
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +2,255 | $8.63 | $19k | 40,571 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -4,730 | $24.18 | $114k | 35,841 | 25 d ago |
| Sep 15, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -822 | $0.00 | $0 | 6,574 | 25 d ago |
| Sep 15, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,019 | $0.00 | $0 | 8,144 | 25 d ago |
| Sep 15, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,255 | $0.00 | $0 | 18,032 | 25 d ago |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 6Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $136k 10,139 shares | -8% | |
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $35k 2,646 shares | +11% | |
| 32Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $30k 2,268 shares | +10% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $25k 1,800 shares | -1% | |
| 38Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $69k 5,040 shares | +29% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Larry Todd Edwards See Remarks | $105k 7,451 shares | -4% | |
| 33Weak | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $34k 2,520 shares | +17% | |
| 44Moderate | ARQTbuy Arcutis Biotherapeutics, Inc. | Patrick J Heron director | $119k 8,674 shares | +138% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.